TN2015000235A1 - Compositions comprising vortioxetine and donepezil - Google Patents
Compositions comprising vortioxetine and donepezilInfo
- Publication number
- TN2015000235A1 TN2015000235A1 TNP2015000235A TN2015000235A TN2015000235A1 TN 2015000235 A1 TN2015000235 A1 TN 2015000235A1 TN P2015000235 A TNP2015000235 A TN P2015000235A TN 2015000235 A TN2015000235 A TN 2015000235A TN 2015000235 A1 TN2015000235 A1 TN 2015000235A1
- Authority
- TN
- Tunisia
- Prior art keywords
- vortioxetine
- donepezil
- compositions
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261736799P | 2012-12-13 | 2012-12-13 | |
PCT/EP2013/076337 WO2014090929A1 (fr) | 2012-12-13 | 2013-12-12 | Compositions comprenant de la vortioxétine et du donépézil |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2015000235A1 true TN2015000235A1 (en) | 2016-10-03 |
Family
ID=49943326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2015000235A TN2015000235A1 (en) | 2012-12-13 | 2015-05-27 | Compositions comprising vortioxetine and donepezil |
Country Status (44)
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218482B (zh) * | 2014-06-24 | 2018-04-06 | 杭州和泽医药科技有限公司 | 沃替西汀氢溴酸盐β晶型的制备方法 |
CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
CN105315184B (zh) * | 2015-06-26 | 2017-03-29 | 上海医药工业研究院 | 一种沃替西汀的制备方法及其中间体 |
BR112018000841A8 (pt) * | 2015-07-17 | 2022-11-22 | Pasteur Institut | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites |
CN105534933A (zh) * | 2016-01-19 | 2016-05-04 | 美吉斯制药(厦门)有限公司 | 一种沃替西汀口腔崩解片及其制备方法 |
WO2018002115A1 (fr) | 2016-07-01 | 2018-01-04 | H. Lundbeck A/S | Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur |
WO2018182639A1 (fr) | 2017-03-30 | 2018-10-04 | Rundle Research, LLC | Méthodes de traitement de la dépression |
US10398691B2 (en) | 2017-03-30 | 2019-09-03 | Rundle Research, LLC | Methods of treating depression |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0268871A1 (fr) | 1986-10-31 | 1988-06-01 | Sumitomo Pharmaceuticals Company, Limited | Dérivés de quinoléine |
IT1225462B (it) | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
AU632458B2 (en) | 1987-05-04 | 1993-01-07 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
EP0403713A1 (fr) | 1989-06-22 | 1990-12-27 | Merrell Dow Pharmaceuticals Inc. | Inhibiteurs d'acétylcholinestérase |
US4914102A (en) | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
TW200462B (fr) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
US5246947A (en) | 1991-09-23 | 1993-09-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression |
US5231093A (en) | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
ES2042384B1 (es) | 1991-12-26 | 1994-06-01 | Boehringer Ingelheim Espana | Procedimiento para obtener derivados bis-piridinicos. |
SE9302080D0 (sv) | 1993-06-16 | 1993-06-16 | Ab Astra | New compounds |
IL126308A0 (en) | 1996-04-12 | 1999-05-09 | Hoechst Marion Roussel Inc | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
WO2003082820A1 (fr) | 2002-03-29 | 2003-10-09 | Eisai Co., Ltd. | Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine) |
DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
JP2006512417A (ja) * | 2002-12-24 | 2006-04-13 | ニューロケム (インターナショナル) リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
MY149152A (en) * | 2006-05-08 | 2013-07-15 | Teikoku Seiyaku Kk | Percutaneous absorption preparations of antimentia drugs |
AU2007258553A1 (en) * | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
EP2439201B1 (fr) | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Composés avec activité combiné sert, 5-ht3 et 5-ht1a |
WO2009005519A1 (fr) * | 2007-06-29 | 2009-01-08 | Accera, Inc. | Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit |
TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
TW201033181A (en) | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
-
2013
- 2013-12-12 GE GEAP201313850A patent/GEP201706739B/en unknown
- 2013-12-12 ME MEP-2018-66A patent/ME03029B/fr unknown
- 2013-12-12 PT PT138187026T patent/PT2931276T/pt unknown
- 2013-12-12 RU RU2015122256A patent/RU2635528C2/ru active
- 2013-12-12 WO PCT/EP2013/076337 patent/WO2014090929A1/fr active Application Filing
- 2013-12-12 ES ES13818702.6T patent/ES2663680T3/es active Active
- 2013-12-12 JP JP2015547020A patent/JP6257641B2/ja active Active
- 2013-12-12 MX MX2015007269A patent/MX362886B/es active IP Right Grant
- 2013-12-12 MY MYPI2015001479A patent/MY171802A/en unknown
- 2013-12-12 NZ NZ708595A patent/NZ708595A/en unknown
- 2013-12-12 KR KR1020157015715A patent/KR102171152B1/ko active IP Right Grant
- 2013-12-12 DK DK13818702.6T patent/DK2931276T3/en active
- 2013-12-12 UA UAA201506381A patent/UA114016C2/uk unknown
- 2013-12-12 AU AU2013357308A patent/AU2013357308B2/en not_active Ceased
- 2013-12-12 US US14/649,087 patent/US9211288B2/en active Active
- 2013-12-12 PE PE2015000879A patent/PE20151026A1/es active IP Right Grant
- 2013-12-12 SI SI201330970T patent/SI2931276T1/en unknown
- 2013-12-12 CN CN201380065034.2A patent/CN104853755B/zh active Active
- 2013-12-12 AP AP2015008498A patent/AP2015008498A0/xx unknown
- 2013-12-12 HU HUE13818702A patent/HUE036280T2/hu unknown
- 2013-12-12 EA EA201590932A patent/EA028300B1/ru not_active IP Right Cessation
- 2013-12-12 RS RS20180285A patent/RS56949B1/sr unknown
- 2013-12-12 EP EP13818702.6A patent/EP2931276B1/fr active Active
- 2013-12-12 LT LTEP13818702.6T patent/LT2931276T/lt unknown
- 2013-12-12 BR BR112015013675-3A patent/BR112015013675B1/pt active IP Right Grant
- 2013-12-12 AR ARP130104651A patent/AR093939A1/es not_active Application Discontinuation
- 2013-12-12 MA MA38253A patent/MA38253B1/fr unknown
- 2013-12-12 CA CA2893468A patent/CA2893468C/fr active Active
- 2013-12-12 PL PL13818702T patent/PL2931276T3/pl unknown
- 2013-12-12 SG SG11201504483YA patent/SG11201504483YA/en unknown
-
2014
- 2014-03-05 NO NO14709546A patent/NO2970700T3/no unknown
-
2015
- 2015-05-27 TN TNP2015000235A patent/TN2015000235A1/fr unknown
- 2015-06-03 IL IL239192A patent/IL239192B/en active IP Right Grant
- 2015-06-03 DO DO2015000133A patent/DOP2015000133A/es unknown
- 2015-06-08 GT GT201500143A patent/GT201500143A/es unknown
- 2015-06-08 PH PH12015501302A patent/PH12015501302B1/en unknown
- 2015-06-09 CR CR20150303A patent/CR20150303A/es unknown
- 2015-06-09 NI NI201500078A patent/NI201500078A/es unknown
- 2015-06-09 EC ECIEPI201523182A patent/ECSP15023182A/es unknown
- 2015-06-10 CL CL2015001615A patent/CL2015001615A1/es unknown
- 2015-06-12 ZA ZA2015/04274A patent/ZA201504274B/en unknown
-
2016
- 2016-01-18 HK HK16100513.0A patent/HK1212601A1/zh unknown
-
2018
- 2018-02-23 HR HRP20180333TT patent/HRP20180333T1/hr unknown
- 2018-03-27 CY CY20181100347T patent/CY1120098T1/el unknown
-
2022
- 2022-05-19 AR ARP220101337A patent/AR125920A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
PH12015501302A1 (en) | Compositions comprising vortioxetine and donepezil | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
GB201106750D0 (en) | Novel compounds | |
IL235767A (en) | Preserved pyrolidines, pharmaceuticals containing them and their uses | |
EP2904106A4 (fr) | Compositions et procédés de ciblage de cellules stromales pour le traitement du cancer | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
GB2501611B (en) | Alpha-2-macroglobulin compositions and therapeutic uses | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
EP2575766A4 (fr) | Nouveaux composés pharmaceutiques | |
HUE039044T2 (hu) | Gyógyászati kompozíció sclerosis multiplex kezelésére |